Literature DB >> 11564596

Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting.

D B Russell1, S N Tabrizi, J M Russell, S M Garland.   

Abstract

BACKGROUND: Genital herpes is usually caused by herpes simplex virus type 2 (HSV-2), with infections often being unrecognised by patients and/or clinicians. HSV-2 infections may be a risk factor for the transmission of human immunodeficiency virus (HIV) infection. Reliable tests for type-specific HSV antibodies are now readily available.
OBJECTIVES: To determine the seroprevalence of HSV-1 and -2 in HIV-seronegative gay men in a primary care setting in Melbourne, Australia, and to compare it with the rate in HIV-infected gay men. To assess the utility in a clinical setting of a type-specific HSV enzyme linked immunosorbent assay (ELISA) as compared with western blot. STUDY
DESIGN: We recruited a total of 300 HIV-seronegative homosexual men attending for HIV antibody testing, and HIV-infected men attending for CD4 lymphocyte count and viral load estimation. The subjects completed a questionnaire, and sera were sent for total IgG HSV testing and testing by Gull type-specific HSV ELISA assay. Selected serum samples were retested by western blotting and the results analysed.
RESULTS: In total, 168 HIV-antibody negative men and 132 HIV-antibody positive men were recruited. Of all subjects, 73.3% had HSV-1 antibodies. This proportion did not differ between HIV-seronegative and seropositive men (P=0.48). About twenty percent of HIV-seronegative men and 61% of HIV-seropositive men had antibodies to HSV-2 (P<0.0001); 75.6% of HIV-seronegative men with antibodies to HSV-2 gave no history of genital herpes, as did 66.7% of HIV-seropositive men. Overall, in using the type-specific ELISA (Gull) assay, false negative, false positive or equivocal results were obtained in 33/300 (11%) of samples tested compared with western blot.
CONCLUSIONS: High rates of HSV-2 infection were found in homosexual males, with the rate for HIV-seropositive men being over twice that for HIV uninfected men. Most subjects were not aware of their infection with HSV-2. HIV-infected individuals were also older and had higher numbers of sexual partners, but we were unable to unambiguously establish that these variables contributed to the difference in HSV-2 seroprevalence rates. The Gull type-specific assay for HSV antibodies has significant problems with sensitivity and specificity at a discrepancy rate of 11%. Caution is advised in using this type-specific commercial assay for clinical purposes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564596     DOI: 10.1016/s1386-6532(01)00203-7

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  14 in total

Review 1.  [Anal herpes simplex virus infections].

Authors:  Albert Rübben
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

2.  Emerging technologies for the detection of viral infections.

Authors:  Peter D Burbelo; Michael J Iadarola; Adrija Chaturvedi
Journal:  Future Virol       Date:  2018-12-14       Impact factor: 1.831

3.  Herpes simplex virus type 2 seroprevalence and incidence in acute and chronic HIV-1 infection.

Authors:  M Lagnese; E S Daar; P Christenson; G Rieg
Journal:  Int J STD AIDS       Date:  2011-07-08       Impact factor: 1.359

4.  Seroepidemiology of herpes simplex virus type 2 (HSV2) in HIV infected patients in Kermanshah-Iran.

Authors:  Alireza Janbakhash; Feizollah Mansouri; Siavash Vaziri; Babak Sayad; Mandana Afsharian; Ahmadreza Abedanpor
Journal:  Caspian J Intern Med       Date:  2012

5.  Antiviral activity of recombinant cyanovirin-N against HSV-1.

Authors:  Hong Yu; Zong-tao Liu; Rui Lv; Wen-qing Zhang
Journal:  Virol Sin       Date:  2010-12-21       Impact factor: 4.327

6.  Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey.

Authors:  A L Cunningham; R Taylor; J Taylor; C Marks; J Shaw; A Mindel
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

7.  The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic.

Authors:  J L Meyer; R A Crosby; W L H Whittington; D Carrell; R Ashley-Morrow; A S Meier; R D Harrington; R DiClemente; A Wald
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 8.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

9.  Altered antibody profiles against common infectious agents in chronic disease.

Authors:  Peter D Burbelo; Kathryn H Ching; Caryn G Morse; Ilias Alevizos; Ahmad Bayat; Jeffrey I Cohen; Mir A Ali; Amit Kapoor; Sarah K Browne; Steven M Holland; Joseph A Kovacs; Michael J Iadarola
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

10.  Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984-2003).

Authors:  Colette Smit; Christiaan Pfrommer; Adrian Mindel; Janette Taylor; Joke Spaargaren; Ben Berkhout; Roel Coutinho; Nicole H T M Dukers
Journal:  Eur J Epidemiol       Date:  2007-10-10       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.